Search research articles
Contact Us
Filters
Showing results (181-190 of 194) with videos related to
Page
of 20
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 8, 2008
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG)
K Spieth, R Kaufmann, R Dummer, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
June 23, 2020
The predictive and prognostic significance of cell-free DNA concentration in melanoma
R Váraljai, S Elouali, S S Lueong, et al.
The British Journal of Dermatology
|
November 13, 2021
Bullous pemphigoid after SARS-CoV-2 vaccination: spike-protein-directed immunofluorescence confocal microscopy and T-cell-receptor studies
T Gambichler, N Hamdani, H Budde, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 9, 2020
Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma
S Ugurel, D Schadendorf, K Horny, et al.
Arthritis and Rheumatism
|
June 10, 2010
The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial
J T Merrill, R Burgos-Vargas, R Westhovens, et al.
Cancer Immunology, Immunotherapy : CII
|
April 19, 2021
Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study
H M Stege, M Haist, S Schultheis, et al.
Annals of the Rheumatic Diseases
|
January 7, 2009
Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
R Westhovens, M Robles, A C Ximenes, et al.
Annals of the Rheumatic Diseases
|
August 9, 2011
Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes
J Bathon, M Robles, A C Ximenes, et al.
Pigment Cell & Melanoma Research
|
February 9, 2010
Multicentre study on standardisation of melanoma cell culture--an initiative of the German Melanoma Research Network
J Eberle, B Spangler, J C Becker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 12, 2011
Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial
F Egberts, R Gutzmer, S Ugurel, et al.
Page
of 20
Search research articles
Search
Showing results (181-190 of 194) with videos related to
Sort By:
Page
of 20
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 8, 2008
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG)
K Spieth, R Kaufmann, R Dummer, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
June 23, 2020
The predictive and prognostic significance of cell-free DNA concentration in melanoma
R Váraljai, S Elouali, S S Lueong, et al.
The British Journal of Dermatology
|
November 13, 2021
Bullous pemphigoid after SARS-CoV-2 vaccination: spike-protein-directed immunofluorescence confocal microscopy and T-cell-receptor studies
T Gambichler, N Hamdani, H Budde, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 9, 2020
Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma
S Ugurel, D Schadendorf, K Horny, et al.
Arthritis and Rheumatism
|
June 10, 2010
The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial
J T Merrill, R Burgos-Vargas, R Westhovens, et al.
Cancer Immunology, Immunotherapy : CII
|
April 19, 2021
Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study
H M Stege, M Haist, S Schultheis, et al.
Annals of the Rheumatic Diseases
|
January 7, 2009
Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
R Westhovens, M Robles, A C Ximenes, et al.
Annals of the Rheumatic Diseases
|
August 9, 2011
Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes
J Bathon, M Robles, A C Ximenes, et al.
Pigment Cell & Melanoma Research
|
February 9, 2010
Multicentre study on standardisation of melanoma cell culture--an initiative of the German Melanoma Research Network
J Eberle, B Spangler, J C Becker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 12, 2011
Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial
F Egberts, R Gutzmer, S Ugurel, et al.
Page
of 20